Related Experiment Video

Updated: Mar 2, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies

Cristina Ilcus1, Cristina Bagacean1,2, Adrian Tempescul3

  • 1Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Oncotargets and Therapy
|May 13, 2017
PubMed

Insights

Programmed cell death (PD)-1 blockade shows promise in treating lymphoid malignancies. Blocking the PD-1 signaling pathway is effective in certain cancers, with ongoing trials for broader application.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • The programmed cell death (PD)-1 receptor on immune cells normally limits immune responses to protect tissues.
  • Its ligands, programmed death ligands (PD-Ls), are expressed by cancer cells, facilitating immune evasion.
  • Blocking the PD-1/PD-L pathway has proven effective in treating certain cancers like melanoma and lung cancer.

Purpose of the Study:

  • To review the role of PD-1 signaling in lymphoid malignancies.
  • To summarize recent clinical trial results for PD-1/PD-L1 blocking agents in these cancers.

Main Methods:

  • Literature review of studies on PD-1 signaling in lymphoid malignancies.
  • Analysis of clinical trial data for PD-1 and PD-L1 inhibitors.

Main Results:

  • PD-1 blockade has shown significant efficacy in lymphoid malignancies.
  • A PD-1 blocking agent is approved for Hodgkin's lymphoma.
  • Early phase trials demonstrate promising results across various lymphoid cancers.

Conclusions:

  • PD-1 signaling plays a crucial role in the immune microenvironment of lymphoid malignancies.
  • PD-1/PD-L1 pathway inhibition represents a promising therapeutic strategy for lymphoid cancers.
  • Ongoing and planned Phase III trials are expected to further establish the efficacy of these agents.
Keywords:
b7 antigenschronic lymphocytic leukemiahematological cancerimmune checkpoint blockadelymphomaprogrammed cell death 1

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.4K